Literature DB >> 28789852

Recombinant Calponin of human filariid Brugia malayi: Secondary structure and immunoprophylactic potential.

Shiv K Verma1, Ashish Arora2, P Kalpana Murthy3.   

Abstract

In the search for potential vaccine candidates for the control of human lymphatic filariasis, we recently identified calponin-like protein, that regulates actin/myosin interactions, in a proinflammatory fraction F8 (45.24-48.64kDa) of Brugia malayi adult worms. In the present study, the gene was cloned, expressed, and the recombinant Calponin of B. malayi (r-ClpBm) was prepared and characterized. r-ClpBm bears homology with OV9M of Onchocerca volvulus, a non-lymphatic filariid that causes loss of vision and cutaneous pathology. r-ClpBm was found to be a ∼45kDa protein that folds into a predominantly α-helix conformation. The protective efficacy of r-ClpBm against B. malayi infection in Mastomys coucha was investigated by assessing the course of microfilaraemia and adult worm burden in the host immunized with r-ClpBm and subsequently infected with infective third stage larvae (L3). Expression of the Calponin was detected in all life stages (microfilariae, L3, L4, L5 and adults) of the parasite and immunization with r-ClpBm partially protected M. coucha against establishment of infection as inferred by ∼42% inhibition in parasite burden. Upregulated cellular proliferation, TNF-α, IFN-γ, IL-1β, IL-4, nitric oxide (NO) release, expression of iNOS, and specific IgG, IgG1 and IgG2b in immunized animals correlated with parasitological findings. r-ClpBm immunization caused degranulation in majority of mast cells indicating possible involvement of mast cell products in reducing the parasite survival. It appears that complex mechanisms including Th1, Th2, NO and mast cells are involved in the clearance of infection. To the best of our knowledge this is the first report on cloning, expression of the gene and purification of r-ClpBm, determination of its secondary structure and its ability to partially prevent establishment of B. malayi infection. Thus, r-ClpBm may further be studied and developed in combination with other protective molecules of B. malayi as a component of potential filarial cocktail vaccine candidate.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brugia malayi; COX-2; Calponin; Cytokines; IgG and its subclasses; LTT assay; iNOS

Mesh:

Substances:

Year:  2017        PMID: 28789852     DOI: 10.1016/j.vaccine.2017.07.105

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Immunoreactivity of Brugia malayi Calreticulin and Its Domains with Sera of Different Categories of Bancroftian Filarial Patients.

Authors:  Sunita Yadav; Smita Gupta; Mohd Saeed; Huma Mustafa; Jitendra Kumar Saxena; Puvvada Kalpana Murthy
Journal:  Acta Parasitol       Date:  2022-01-27       Impact factor: 1.440

2.  Troponin 1 of human filarial parasite Brugia malayi: cDNA cloning, expression, purification, and its immunoprophylactic potential.

Authors:  Vikas Kushwaha; Prachi Tewari; Payal Mandal; Anurag Tripathi; P Kalpana Murthy
Journal:  Parasitol Res       Date:  2019-05-04       Impact factor: 2.289

Review 3.  Mastomys Species as Model Systems for Infectious Diseases.

Authors:  Daniel Hasche; Frank Rösl
Journal:  Viruses       Date:  2019-02-21       Impact factor: 5.048

4.  Immunolocalization of Disorganized Muscle Protein-1 in Different Life Stages of Human Lymphatic Filariid, Brugia malayi.

Authors:  Vikas Kushwaha; Amogh A Sahasrabuddhe; P Kalpana Murthy
Journal:  Acta Parasitol       Date:  2020-06-04       Impact factor: 1.440

5.  Evaluating the Vaccine Potential of a Tetravalent Fusion Protein (rBmHAXT) Vaccine Antigen Against Lymphatic Filariasis in a Mouse Model.

Authors:  Nikhil Chauhan; Vishal Khatri; Priyankana Banerjee; Ramaswamy Kalyanasundaram
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

Review 6.  Highlighting the Relevance of CD8+ T Cells in Filarial Infections.

Authors:  Alexander Kwarteng; Ebenezer Asiedu; Kelvin Kwaku Koranteng; Samuel Opoku Asiedu
Journal:  Front Immunol       Date:  2021-09-16       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.